Global X Genomics & Biotechnology ETF
GNOM
60 hedge funds and large institutions have $67.2M invested in Global X Genomics & Biotechnology ETF in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 17 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
0% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 17
0.04% less ownership
Funds ownership: 10.8% → 10.77% (-0.04%)
2% less funds holding
Funds holding: 61 → 60 (-1)
37% less capital invested
Capital invested by funds: $107M → $67.2M (-$40M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCM
One Capital Management
Westlake Village,
California
|
+$5.63M |
| 2 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$2.41M |
| 3 |
MML Investors Services
Springfield,
Massachusetts
|
+$1.67M |
| 4 |
MIG
McGuire Investment Group
Wakefield,
Rhode Island
|
+$1.47M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$732K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$17.7M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.59M |
| 3 |
CW
CreativeOne Wealth
Overland Park,
Kansas
|
-$2.3M |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$1.48M |
| 5 |
JIP
Jaffetilchin Investment Partners
Tampa,
Florida
|
-$1.34M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Wells Fargo
San Francisco,
California
| – | -$23.7K | -375 | Closed |
|
|
PA
77
Parallel Advisors
San Francisco,
California
| – | -$3K | -34 | Closed |
|
GNOM Hedge Fund Activity: Q1 2022 in Review
60 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Global X Genomics & Biotechnology ETF (GNOM) for Q1 2022, worth a combined $67.2M — down 37% from $107M a quarter earlier.
Fund positioning in GNOM was balanced in Q1 2022: 17 funds opened new positions, 17 closed out, 18 added to existing stakes and 15 trimmed.
The largest buyer was One Capital Management, opening a new position worth an estimated $5.63M. The largest seller was Mirae Asset Global Investments, cutting an estimated $17.7M.
- 60 institutional investors held Global X Genomics & Biotechnology ETF (GNOM) as of Q1 2022, down from 61 in Q4 2021.
- Funds reported $67.2M of Global X Genomics & Biotechnology ETF stock for Q1 2022, down 37% quarter-over-quarter.
- 17 funds opened new Global X Genomics & Biotechnology ETF positions in Q1 2022 and 17 closed out, a net change of 0 holders.
- The largest Global X Genomics & Biotechnology ETF buyer in Q1 2022 was One Capital Management, an estimated $5.63M added.
- The largest Global X Genomics & Biotechnology ETF seller in Q1 2022 was Mirae Asset Global Investments, an estimated $17.7M sold.
Based on aggregated 13F filings for Q1 2022.